Previous 10 | Next 10 |
home / stock / seovf / seovf news
LONDON, Ontario, June 15, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp, will be participating in t...
Researchers from the Dr. Piotr Witkowski Laboratory at the University of Chicago presented updated data on six patients with type 1 diabetes and hypoglycemia unawareness The first three patients have been insulin independent for over 2 years, 6 months, and 3 months, respective...
(TheNewswire) London, Ontario – TheNewswire - June 1 , 2022 – Sernova Corp. (TSXV:SVA ) ; ( OTC:SEOVF ) ; ( FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeut...
(TheNewswire) London, Ontario – TheNewswire - May 24 , 2022 – Sernova Corp. (TSXV:SVA; ) ( OTC:SEOVF ) ; ( FSE: PSH); ( XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell t...
Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta Cells Partners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent Diabetes ...
Germany-based Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and Canada's Sernova (OTCQB:SEOVF) are collaborating to develop a therapy for diabetes. The companies plan to develop an implantable iPSC-based beta cell replacement therapy to treat insulin-dependent diabetes, including type 1 and 2. Under...
(TheNewswire) LONDON, ONTARIO – TheNewswire - May 9, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D...
(TheNewswire) Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes LONDON, ONTARIO – TheNewswire - May 5, 2022 – Sernova Corp. (TSXV:SVA)...
(TheNewswire) LONDON, ONTARIO – TheNewswire - April 29, 2022 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and...
(TheNewswire) Confirms Ongoing Safety and Tolerability of Sernova’s Cell Pouch LONDON, ONTARIO – TheNewswire - March 17, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical- stage company and leader in regenerative medicine cell the...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...